Affiliation:
1. Department of Oncology The Affiliated Cancer Hospital of Nanjing Medical University Nanjing China
2. Department of Chemotherapy Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University Nanjing China
Abstract
AbstractBackgroundTaxanes are the basic components of breast cancer chemotherapy. Nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) shows improved antitumor effects because of more targeted delivery. However, the effects of nab‐paclitaxel have not been systematically studied in patients with metastatic breast cancer (MBC) pretreated with taxanes. Considering the limited treatment options for MBC, this study retrospectively evaluated the clinical efficacy and adverse effects of nab‐paclitaxel in patients with taxane‐pretreated MBC.MethodsPatients who had previously received taxanes and subsequently received nab‐paclitaxel chemotherapy for MBC at Jiangsu Cancer Hospital between October 2014 and April 2022 were included for analysis. The primary end point was progression‐free survival (PFS), and the secondary end points were the objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), and side effects.ResultsA total of 236 female patients with MBC were included. The median PFS was 7.20 months (95% confidence interval [CI], 6.63–7.80 months), and the ORR, DCR, and CBR were 29.55% (95% CI, 23.50%–35.60%), 83.64% (95% CI, 78.70%–88.60%), and 56.36% (95% CI, 49.80%–63.00%), respectively. Following nab‐paclitaxel treatment, the median PFS of patients who were sensitive to taxanes during previous treatments was significantly longer than that of patients who were resistant to taxanes (7.57 months vs. 4.43 months, p < .001). The most common adverse events were sensory neuropathy (89.83%), neutropenia (48.73%), leukopenia (46.61%), and anemia (35.59%).ConclusionNab‐paclitaxel demonstrated clinical activity in taxane‐pretreated patients with MBC. This beneficial effect was observed both in patients who were sensitive and resistant to taxanes during previous treatments. These results suggest nab‐paclitaxel as the preferred chemotherapy regimen in patients with MBC, regardless of their sensitivity to taxanes during previous treatments.